AOD-9604 HSA/FSA Eligibility and Submission: What You Can Actually Do in 2026

What AOD-9604 Is and Why the Regulatory Status Matters for Reimbursement

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the lipolytic region of human growth hormone (positions 176-191 of the native sequence). No FDA-approved finished drug product for AOD-9604 exists as of 2026. The FDA's Office of Pharmaceutical Quality classifies it as a bulk drug substance that may be used in compounding under specific conditions.

That regulatory gap matters for your wallet. Because no commercial product exists, the only legal U.S. Source is a 503A compounding pharmacy operating under a patient-specific prescription. The IRS does not require FDA approval for a drug to qualify under HSA/FSA rules. It requires that the expense be for "the diagnosis, cure, mitigation, treatment, or prevention of disease," as stated in IRS Publication 502.

How 503A Status Affects Eligibility

A 503A pharmacy compounds for individual patients under a prescription from a licensed practitioner. That prescription is the document that anchors your reimbursement claim. Without it, no HSA or FSA administrator will process the expense, because the payment would not qualify as a prescribed drug under 26 U.S.C. § 213(d).

The IRS confirmed in Revenue Procedure 2025-19 that the HSA contribution limits for 2026 are $4,300 (self-only) and $8,550 (family), and reiterated that compounded prescription medications remain qualified medical expenses when prescribed by a licensed provider for a diagnosed condition.

The Obesity and Metabolic Disease Connection

AOD-9604 has been studied for its effect on adipose tissue metabolism. A Phase IIb trial published in the journal Obesity Research (ClinReports Australia, reference CAN-AOD-2001) tested oral AOD-9604 at doses of 1 mg daily against placebo in overweight adults over 24 weeks. The NIH National Library of Medicine hosts the foundational pharmacology data confirming the peptide's interaction with beta-3 adrenergic receptors in adipocytes. Establishing a formal diagnosis of obesity (ICD-10 E66.x) or metabolic syndrome in your medical record is the strongest path to a defensible HSA/FSA claim, because it links the prescription to a diagnosable condition.

The American Association of Clinical Endocrinology (AACE) 2022 clinical practice guideline on obesity defines obesity as a chronic disease requiring active medical management, a position documented in their consensus statement available via academic.oup.com. Framing AOD-9604 use within that disease-management context is what makes the expense defensible to a plan administrator.

IRS Rules That Govern Compounded Drug Reimbursement

The Internal Revenue Service sets the eligibility floor. Your HSA or FSA administrator cannot reimburse expenses that fall outside IRS definitions, and it cannot deny a claim that legitimately falls inside them.

The Section 213(d) Standard

Under 26 U.S.C. § 213(d)(1)(A), a medical expense is any amount paid "for the diagnosis, cure, mitigation, treatment, or prevention of disease." Compounded drugs prescribed by a licensed practitioner have satisfied this standard since the IRS clarified the rule in Notice 2010-59. The IRS does not maintain a positive list of approved drugs. It delegates that determination to whether a valid prescription exists and whether the substance is used for a qualifying medical purpose.

IRS Notice 2010-59 states: "The cost of prescribed drugs is a medical expense. A prescribed drug is one that requires a prescription by a physician for its use by an individual." That definition covers compounded peptides dispensed under a prescription.

What "Prescribed" Means in Practice

The prescription must come from a licensed practitioner with authority to prescribe in the state where the patient is located. It must specify the drug name, strength, dosing instructions, and the prescribing provider's DEA or NPI number. A wellness consultation that produces a generic "supplement recommendation" does not satisfy this standard. An actual prescription on provider letterhead transmitted to a 503A pharmacy does.

The FDA's 2018 guidance on 503A compounding pharmacies outlines what constitutes a valid prescription for compounded drugs, providing the regulatory foundation administrators use when auditing claims.

Over-the-Counter Exclusion Does Not Apply

Some administrators incorrectly flag peptide reimbursement requests under the over-the-counter drug rules introduced by the ACA (later modified by the CARES Act of 2020). The CARES Act, codified at 26 U.S.C. § 223, restored OTC drug eligibility but also confirmed that prescribed compounded medications were never excluded. AOD-9604 is not available over the counter anywhere in the United States, so the OTC question is not applicable to any properly documented AOD-9604 claim.

The Five Documents You Need Before Submitting a Claim

Getting reimbursed is a documentation exercise. Missing even one item causes denial.

Document 1: Valid Prescription

The prescription must include your full legal name, date of birth, drug name (AOD-9604 or HGH fragment 176-191), concentration (typically 300 mcg/dose to 500 mcg/dose for subcutaneous injection), quantity dispensed, prescriber name, prescriber NPI or DEA number, and date written. Ask the pharmacy to include the NDC-equivalent compounding code on the receipt even though compounded drugs do not carry standard NDCs.

Document 2: Itemized Pharmacy Receipt

The receipt must show the pharmacy name and license number, patient name, drug name, dispense date, quantity, and amount paid. A credit card statement alone is never sufficient for an HSA or FSA claim, according to IRS Publication 969 (Health Savings Accounts and Other Tax-Favored Health Plans).

Document 3: Letter of Medical Necessity (LMN)

An LMN is a signed statement from your prescribing provider explaining why AOD-9604 is medically necessary for your specific diagnosis. A strong LMN references the ICD-10 code (e.g., E66.01 for morbid obesity due to excess calories, or E88.81 for metabolic syndrome), describes the clinical rationale, and states that the prescription is for treatment rather than general wellness. Administrators are far less likely to deny a claim backed by a detailed LMN.

Document 4: Proof of HSA/FSA Account Ownership

Some third-party administrators require the last four digits of your HSA account or FSA plan ID on the claim form. Have your plan card or welcome letter available.

Document 5: Completed Claim Form

Every administrator has its own form. Payflex, HealthEquity, WEX, and Optum Bank all publish downloadable PDF claim forms on their member portals. Fill in every field. Incomplete forms are the single most common reason for first-round denials, a pattern noted in consumer guidance published by the U.S. Department of the Treasury's HSA FAQ page.

Step-by-Step Submission Process

The process below applies to the major U.S. HSA and FSA administrators as of 2026.

Step 1: Confirm Plan Rules Before You Pay

Call the member services number on the back of your benefits card. Ask specifically: "Does my plan reimburse compounded prescription drugs dispensed by a 503A pharmacy?" Some employer-sponsored FSAs add plan-level exclusions on top of IRS minimums. Knowing your plan's rules before you spend prevents surprises.

Step 2: Pay Out of Pocket at the Pharmacy

Most 503A compounding pharmacies do not have direct billing agreements with FSA debit card networks, because they lack the Inventory Information Approval System (IIAS) certification required for automatic card approval. Pay by personal credit card or check, then submit for reimbursement. A small number of compounding pharmacies have pursued IIAS certification. Ask your pharmacy directly whether its point-of-sale system accepts FSA debit cards.

The FDA's guidance on pharmacy compounding under the FDCA explains the regulatory framework that governs 503A pharmacies, which is the framework administrators use to evaluate reimbursement requests.

Step 3: Gather All Five Documents

Compile the prescription, itemized receipt, LMN, account information, and claim form before you start the online submission. Uploading a complete packet in one session reduces processing time from an average of 10-14 business days to roughly 5-7 business days at most major administrators.

Step 4: Submit Online or by Mail

Log into your administrator's member portal. Manage to "File a Claim" or "Submit Receipt." Upload the documents as a single PDF where the portal permits this. If submitting by mail, send copies only and keep originals.

Step 5: Track and Appeal if Denied

Set a calendar reminder for 15 business days after submission. If denied, request the denial reason in writing. The two most common denial reasons for compounded peptides are "insufficient documentation" and "expense not substantiated as prescribed drug." Both are addressable with the LMN and a copy of the prescription.

The appeals process is described in IRS Publication 969: you have the right to appeal any denial, and administrators must provide a written explanation. If the appeal fails and you believe the denial is incorrect, you can request a formal review from your plan's fiduciary or consult a tax advisor about deducting the expense on Schedule A (subject to the 7.5% AGI floor under 26 U.S.C. § 213).

How to Reduce AOD-9604 Costs Beyond HSA/FSA Savings

HSA and FSA contributions are pre-tax, which saves you the marginal tax rate on whatever you spend. For someone in the 22% federal bracket spending $250/month ($3,000/year), that is $660 in annual tax savings. These additional strategies reduce the remaining out-of-pocket cost further.

Telehealth Prescribing Reduces Consultation Fees

Telehealth consultations for peptide therapy average $99-$199 for an initial visit at HealthRX-affiliated practices, compared to $250-$450 for in-person specialist visits. The CARES Act extension permits telehealth prescribing for non-controlled substances through December 31, 2026, as confirmed by the HHS Office of the Assistant Secretary for Health telehealth policy update. Consultation fees are themselves HSA/FSA-eligible expenses under IRS Publication 502.

Compounding Pharmacy Pricing Varies Significantly

AOD-9604 is not a scheduled substance and is not subject to DEA controlled-substance pricing rules. Monthly costs at 503A pharmacies range from approximately $150 to $350 for a standard injectable protocol (300 mcg subcutaneous, five days per week). Calling three or four PCAB-accredited pharmacies and asking for a cash-pay price sheet is a legitimate cost-comparison strategy. The Pharmacy Compounding Accreditation Board (PCAB) accreditation program is administered through the National Association of Boards of Pharmacy, which publishes a searchable directory of accredited compounders.

Multi-Month Supplies

Some pharmacies discount multi-month supplies by 10-15%. A 90-day supply may cost less per dose than three separate 30-day fills. Confirm with your FSA administrator whether a 90-day compounded supply is reimbursable as a single expense or requires splitting across benefit periods.

Stack Pre-Tax Dollars Strategically

If your employer offers both an HSA-eligible high-deductible health plan and a dependent-care FSA, you can run both simultaneously for different expense categories. You cannot, however, contribute to both a general-purpose FSA and an HSA in the same year unless the FSA is a "limited-purpose FSA" (restricted to dental and vision). IRS Publication 969 explains the interaction rules in detail.

Clinical Context: What the Research Shows About AOD-9604

Understanding the clinical evidence behind AOD-9604 strengthens the medical-necessity argument in your LMN.

Mechanism of Action

AOD-9604 selectively stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor activation without activating growth hormone receptors or elevating IGF-1 levels. A 2001 study in the American Journal of Physiology demonstrated that the 176-191 fragment retains the anti-obesity properties of full-length growth hormone while eliminating the diabetogenic and proliferative effects associated with IGF-1 elevation. That receptor selectivity is part of why clinicians prescribe it for patients where IGF-1 elevation is contraindicated.

Human Trial Data

A randomized controlled trial by Heffernan et al. Examined AOD-9604 in obese male subjects and found statistically significant reductions in body fat mass compared to placebo. The trial data, indexed on PubMed, reported that AOD-9604 at 500 mcg/day produced measurable changes in fat oxidation markers over 12 weeks (PMID: 11375313). The effect size was modest by GLP-1 agonist standards. STEP-1 (N=1,961), the key semaglutide 2.4 mg trial published in the NEJM, showed 14.9% mean body weight reduction at 68 weeks vs. 2.4% with placebo (P<0.001). AOD-9604 trials reported 1-2 kg fat-mass reductions over comparable periods, which is why many clinicians use it as an adjunct to GLP-1 therapy rather than a standalone weight-loss agent.

Safety Profile Relevant to Medical Necessity

A Phase I safety study published via ClinicalTrials.gov (NCT00763022) reported no serious adverse events at doses up to 1,000 mcg/day over 12 weeks in healthy adults. The absence of IGF-1 elevation is the primary safety differentiator from full-length growth hormone, as documented in the FDA's pharmacology review framework for growth hormone secretagogues. This safety data supports the LMN argument that AOD-9604 is a targeted medical intervention for a diagnosed metabolic condition, not a general wellness product.

Obesity as the Anchor Diagnosis

The CDC defines obesity (BMI 30 or above) as affecting 41.9% of U.S. Adults as of the most recent National Health and Nutrition Examination Survey data, published on the CDC's obesity data page. For patients with a BMI at or above 30, or a BMI at or above 27 with a comorbidity such as type 2 diabetes or hypertension, a medical-necessity argument for a fat-metabolism-targeted peptide is clinically grounded and documentable. The AACE obesity guideline states: "Obesity is a chronic, relapsing, multifactorial disease that requires long-term management strategies individualized to patient physiology and comorbidities," as published in the Journal of Clinical Endocrinology and Metabolism.

Common Denial Scenarios and How to Address Them

Denial: "Not a Covered Drug"

This denial typically means the administrator searched a drug database and found no entry for AOD-9604. Respond with: the IRS does not require a drug to appear in a commercial formulary to qualify under Section 213(d); the eligibility requirement is a valid prescription for a diagnosed medical condition. Attach the prescription and LMN.

Denial: "Insufficient Documentation"

Resubmit with all five documents compiled into a single PDF. Write a one-paragraph cover letter citing IRS Notice 2010-59 and IRS Publication 502. IRS Publication 502 is publicly available at irs.gov and explicitly states that the cost of prescription drugs is a medical expense.

Denial: "Experimental or Investigational"

This is the hardest denial to overturn. Respond by citing the published human trial data (PMID 11375313), the active clinical trial history on ClinicalTrials.gov, and your provider's LMN explaining why the prescription is for active treatment of a diagnosed condition. The IRS standard is medical necessity, not FDA approval. The FDA itself distinguishes between unapproved drugs and compounded drugs under valid prescriptions in its 2018 compounding guidance.

Denial: "Wellness or Cosmetic Expense"

This denial is overturned by the LMN alone if it is written correctly. The LMN must reference a specific ICD-10 diagnosis code and explain how AOD-9604 treats that condition. Language like "prescribed for body composition optimization" is not adequate. Language like "prescribed for treatment of obesity (E66.01) with impaired fat oxidation unresponsive to diet and exercise alone" is.

2026 Program and Policy Updates Affecting AOD-9604 Access

The FDA's 2024-2025 review of bulk drug substances used in 503A compounding produced a revised list. AOD-9604 was not placed on the FDA's Category 1 (appropriate for use) or Category 2 (not appropriate for use) final lists as of the publication date of this article, meaning it continues to be available for patient-specific compounding under the existing regulatory framework. Monitor the FDA's bulk drug substance list for 503A compounding here for any updates that could affect access.

IRS contribution limits for 2026, confirmed in IRS Revenue Procedure 2025-19, are $4,300 for self-only HSA coverage and $8,550 for family coverage. HSA funds roll over indefinitely. FSA funds are subject to plan-specific carryover rules (maximum $660 carryover in 2026, or a 2.5-month grace period, depending on your employer's plan design), per IRS Notice 2005-86.